plasmodium
vivax
second
import
plasmodium
speci
term
epidemiolog
signific
estim
million
malaria
case
global
half
total
number
malaria
case
occur
outsid
africa
although
parasit
classic
consid
benign
sever
featur
make
difficult
control
elimin
first
sever
lethal
p
vivax
malaria
case
report
second
chloroquineresist
strain
recent
emerg
least
one
case
confirm
countri
third
parasit
speci
produc
hypnozoiteform
upon
period
reactiv
induc
clinic
relaps
even
individu
left
endem
region
fourth
gametocyt
emerg
earli
erythrocyt
cycl
possibl
increas
transmiss
difficulti
control
p
vivax
area
two
speci
coexist
incid
appear
decreas
slowli
plasmodium
falciparum
due
limit
associ
classic
malaria
control
measur
vaccin
malaria
current
consid
potenti
valuabl
costeffect
complement
malaria
control
activ
would
significantli
contribut
elimin
last
decad
signific
effort
invest
develop
p
falciparum
recent
p
vivax
vaccin
howev
discoveri
new
potenti
vaccin
candid
requir
use
bioinformat
tool
allow
explor
malaria
genomeproteom
databas
identifi
parasit
protein
contain
specif
domain
function
import
parasit
could
immunolog
target
therefor
repres
novel
candid
antigen
vaccin
develop
protein
coil
coil
stabl
structur
capabl
elicit
antibodi
abl
block
function
domain
differ
microorgan
motif
investig
influenza
viru
coronavirus
malaria
parasit
case
p
falciparum
coil
coil
motif
identifi
silico
protein
predict
differ
cellular
locat
cytoplasm
nucleu
mitochondria
peroxysom
addit
tran
membran
segment
therefor
synthet
peptid
contain
motif
synthes
test
reactiv
serum
obtain
adult
donor
burkina
faso
tanzania
colombia
recogn
antigen
select
specif
human
igg
antibodi
affin
purifi
test
vitro
use
antibodydepend
inhibit
adci
assay
show
sever
activ
inhibit
vitro
parasit
growth
associ
antibodi
respons
protect
infect
also
observ
case
p
vivax
coil
coil
segment
extens
homolog
p
falciparum
counterpart
identifi
silico
synthes
segment
test
reactiv
serum
individu
malaria
endem
area
howev
due
lack
p
vivax
vitro
cultur
function
activ
antibodi
elicit
antigen
yet
studi
parasit
speci
similarli
report
relationship
antibodi
respons
p
vivax
coil
coil
antigen
risk
infect
clinic
malaria
order
explor
associ
total
igg
antibodi
p
vivax
coil
coil
segment
select
base
antigen
risk
diseas
baselin
plasma
sampl
cohort
children
papua
new
guinea
png
test
use
multiplex
bead
array
assay
cohort
children
age
year
enrol
activ
follow
month
identifi
factor
associ
either
risk
protect
infect
diseas
molecular
forc
bloodstag
infect
molfob
individu
level
also
assess
exposur
p
vivax
infect
vari
greatli
clone
acquir
entir
studi
period
children
found
acquir
averag
new
p
vivax
bloodstag
cloneschild
per
yearatrisk
estim
molfob
high
resolut
genotyp
parasit
despit
high
endem
incid
clinic
p
vivax
malaria
decreas
approxim
episod
episod
per
year
suggest
acquisit
clinic
immun
young
age
present
studi
identifi
first
time
number
p
vivax
coil
coil
segment
strongli
associ
protect
clinic
diseas
futur
studi
help
assess
valu
coil
coil
antigen
identifi
marker
acquir
immun
vaccin
candid
blood
sampl
collect
rural
area
near
maprik
east
sepik
provinc
png
includ
children
age
year
enrol
children
activ
followedup
everi
week
clinic
examin
malaria
sign
symptom
bloodsampl
collect
everi
week
period
month
addit
sampl
collect
passiv
case
detect
health
center
malaria
case
confirm
rapid
diagnost
test
rdt
sampl
screen
p
vivax
p
falciparum
p
malaria
p
oval
semiquantit
postpcr
ligas
detect
reactionfluoresc
microspher
assay
ldrfma
p
vivax
posit
sampl
genotyp
use
marker
p
falciparum
posit
sampl
use
marker
total
plasma
sampl
collect
baselin
select
children
complet
followup
use
test
antibodi
reactiv
p
vivax
coil
coil
peptid
p
vivax
clinic
malaria
episod
defin
presenc
fever
ie
axillari
temperatur
plu
parasitemia
written
inform
consent
obtain
parent
guardian
prior
recruit
child
scientif
approv
ethic
clearanc
studi
obtain
medic
research
advisori
committe
mrac
ministri
health
png
institut
review
board
irb
png
institut
medic
research
irb
human
research
ethic
committe
walter
eliza
hall
institut
twentyfour
coil
coil
p
vivax
polypeptid
amino
acid
previous
describ
select
base
reactiv
png
colombia
igg
antibodi
use
test
antibodi
reactiv
png
sampl
briefli
peptid
synthes
fluorenylmethoxycarbonyl
fmoc
solidphas
chemistri
use
intavi
ag
bioanalyt
synthes
germani
tabl
result
polypeptid
hplcpurifi
puriti
confirm
analyt
hplc
mass
spectrometri
malditof
appli
biosystem
foster
citi
ca
reagent
purchas
fluka
buch
switzerland
novabiochem
laufelfingen
switzerland
bioplex
carboxyl
bead
biorad
coval
coat
differ
coil
coil
polypeptid
follow
manufactur
instruct
bioplex
amin
coupl
kit
briefli
microspher
beadsml
activ
mixtur
nhydroxysulfosuccinimid
n
hydrochlorid
min
room
temperatur
rt
dark
microspher
wash
twice
pb
resuspend
pb
ph
polypeptid
ad
microspher
incub
overnight
resuspend
block
buffer
pb
bsa
incub
rotat
rt
minut
bead
wash
pb
store
protect
light
use
coupl
bead
use
analyz
plasma
reactiv
describ
previous
briefli
experiment
plasma
sampl
control
vortex
centrifug
maximum
speed
minut
microcentrifug
eppendorf
dilut
pb
plu
tween
pbt
ad
previous
mix
bead
incub
room
temperatur
protect
light
min
wash
time
pbt
aliquot
rphycoerythrin
conjug
antihuman
igg
produc
donkey
jackson
immuno
research
dilut
ad
incub
min
bead
wash
resuspend
pbt
read
bioplex
plate
also
contain
blank
well
contain
bead
pbt
neg
control
consist
pool
plasma
sampl
individu
never
expos
malaria
dilut
posit
control
consist
serial
dilut
pool
serum
n
png
immun
adult
luminex
median
fluoresc
intens
mfi
valu
convert
arbitrari
antibodi
unit
base
paramet
estim
standard
curv
made
dilut
highlyimmun
png
posit
control
pool
previous
describ
antibodi
unit
rang
ie
equival
dilut
immun
pool
cutoff
posit
calcul
three
standard
deviat
dilut
valu
neg
control
antigen
individu
consid
seroposit
dilut
experiment
plasma
sampl
higher
cutoff
neg
control
cutoff
sampl
test
duplic
two
independ
experi
differ
preval
igg
antibodi
age
infect
statu
exposur
assess
use
fisher
exact
test
spearman
rank
correl
coeffici
use
investig
relationship
among
antibodi
respons
coil
coil
antigen
heat
map
creat
use
corrplot
function
r
associ
antibodi
level
p
vivax
coil
coil
antigen
protect
clinic
malaria
defin
fever
parasit
densiti
well
associ
number
recogn
antigen
risk
p
vivax
clinic
episod
assess
use
neg
binomi
gee
model
exchang
correl
structur
semirobust
varianc
estim
igg
level
classifi
tercil
analys
done
compar
children
low
versu
medium
high
antibodi
level
gee
model
adjust
season
trend
villag
resid
age
individu
differ
exposur
molfob
multivari
analysi
antigen
also
perform
use
backward
stepwis
regress
select
final
model
analys
perform
use
stata
version
statacorp
r
version
expect
base
select
criteria
peptid
plasma
sampl
collect
enrol
reactiv
peptid
variabl
frequenc
tabl
eight
peptid
highest
percentag
respond
children
reactiv
wherea
one
peptid
respond
overal
sampl
antibodi
reactiv
least
peptid
wherea
sampl
show
reaction
peptid
test
fig
plasma
sampl
n
react
antigen
infect
sampl
time
although
sampl
infect
sampl
react
antigen
differ
ilahita
sunuhu
villag
regard
malaria
preval
age
enrol
percentag
infect
children
enrol
higher
sunuhu
ilahita
respect
p
reason
reactiv
total
igg
children
two
villag
compar
children
sunuhu
like
igg
antibodi
reactiv
peptid
although
signific
differ
observ
seven
tabl
higher
posit
observ
two
hamlet
ilahita
sunuhu
antigen
tabl
posit
correl
observ
antibodi
posit
coil
coil
peptid
p
vivax
infect
enrol
tabl
stronger
associ
peptid
p
one
peptid
associ
infect
statu
tabl
signific
associ
antibodi
level
coil
coil
peptid
age
exposur
measur
genotyp
followup
tabl
arbitrari
antibodi
unit
observ
coil
coil
antigen
posit
correl
fig
correl
r
r
r
less
correl
antigen
month
followup
children
experienc
incid
rate
ci
clinic
malaria
episod
adjust
gee
model
appli
test
whether
respons
coil
coil
antigen
associ
risk
clinic
diseas
significantli
lower
risk
clinic
p
vivax
malaria
associ
high
level
igg
coil
coil
antigen
tabl
adjust
incid
rate
ratio
airr
rang
adjust
confound
age
villag
resid
season
individu
differ
exposur
igg
level
coil
coil
antigen
remain
associ
protect
airr
rang
medium
high
level
igg
coil
coil
fragment
associ
protect
high
medium
igg
level
significantli
associ
protect
fig
tabl
gener
strong
associ
increas
antibodi
level
protect
coil
coil
fragment
except
addit
associ
number
recogn
antigen
risk
p
vivax
clinic
episod
assess
identifi
addit
recogn
antigen
reduct
p
vivax
clinic
risk
airr
p
ci
final
multivari
analys
backward
stepwis
regress
perform
antibodi
level
airr
multi
p
ci
remain
significantli
associ
reduc
risk
p
vivax
clinic
diseas
igg
respons
p
vivax
coil
coil
antigen
associ
protect
p
falciparum
clinic
episod
suggest
associ
observ
speciesspecif
tabl
repeat
exposur
malaria
infect
result
develop
clinic
immun
multifactori
process
antibodi
play
major
role
polyclon
monoclon
antibodi
shown
potenti
prevent
malaria
infect
complet
clear
parasitemia
plasmodium
coil
coil
domain
previous
propos
potenti
target
human
malaria
vaccin
develop
sinc
domain
fold
stabl
structur
capabl
elicit
antibodi
reactiv
parasit
function
epitop
gener
non
littl
polymorph
select
p
vivax
antigen
could
repres
challeng
due
technic
difficulti
limit
present
lack
vitro
cultur
system
parasit
speci
previous
natur
acquir
antibodi
p
vivax
merozoit
surfac
protein
bindinginhibitori
antibodi
respons
p
vivax
duffi
bind
protein
pvdbp
associ
reduc
risk
p
vivax
clinic
manifest
individu
brazilian
amazon
region
addit
contribut
antibodi
titer
acquisit
protect
clinic
diseas
assess
cohort
children
png
popul
immun
clinic
p
vivax
malaria
acquir
young
age
decreas
episod
age
year
previou
studi
use
cohort
demonstr
strong
associ
specif
igg
merozoit
surfac
protein
three
novel
merozoit
protein
well
reticulocyt
specif
binder
clinic
protect
use
png
cohort
demonstr
p
vivax
coil
coil
antigen
also
target
natur
acquir
immun
reactiv
plasma
plasmodium
speci
includ
p
vivax
p
falciparum
expos
infect
children
antibodi
reactiv
observ
recruit
time
associ
acquisit
protect
immun
p
vivax
clinic
diseas
found
children
high
antibodi
level
coil
coil
antigen
fold
lower
risk
clinic
p
vivax
malaria
followup
addit
posit
associ
number
recogn
antigen
protect
p
vivax
clinic
episod
also
found
corrobor
role
acquir
immun
explan
decreas
incid
p
vivax
clinic
diseas
increas
age
despit
constant
exposur
multivari
analysi
reveal
antibodi
level
antigen
significantli
associ
reduc
risk
clinic
malaria
may
indic
fragment
particularli
target
natur
immun
good
marker
immun
given
high
correl
antibodi
respons
coil
coil
fragment
difficult
differenti
coacquisit
antibodi
cross
reactiv
multivari
analys
correl
observ
even
though
antigen
deriv
complet
differ
protein
limit
sequenc
homolog
among
peptid
except
show
high
level
homolog
although
crossreact
like
peptid
test
use
individu
sampl
sever
individu
donor
uniqu
set
peptid
recogn
except
recogn
none
peptid
fig
addit
use
affinitypurifi
antibodi
crossreact
observ
p
falciparum
protein
sequenc
ortholog
p
vivax
therefor
research
differ
popul
expos
p
vivax
howev
warrant
confirm
associ
serum
sampl
png
reactiv
p
vivax
coil
coil
peptid
test
case
preval
compar
previous
observ
use
adult
sera
differ
png
region
moreov
children
infect
baselin
plasma
show
reactiv
antigen
data
suggest
antigen
could
marker
recent
exposur
increas
reactiv
p
vivax
coil
coil
peptid
observ
children
live
villag
exposur
p
falciparum
higher
ilahita
sunuhu
observ
could
explain
high
homolog
observ
p
falciparum
p
vivax
coil
coil
antigen
inde
crossreact
p
vivax
peptid
observ
sera
african
donor
supplementari
result
tabl
howev
png
cohort
associ
antibodi
respons
p
vivax
antigen
protect
clinic
p
falciparum
malaria
even
though
number
clinic
episod
p
falciparum
p
vivax
similar
evid
acquisit
clinic
immun
p
falciparum
age
group
cover
cohort
result
correl
previou
studi
use
studi
cohort
signific
associ
observ
antibodi
respons
p
vivax
protein
risk
p
falciparum
clinic
episod
could
explain
differ
age
immun
acquisit
decreas
risk
infect
p
falciparum
seen
adolesc
earli
adulthood
data
present
along
previous
publish
point
select
coil
coil
p
vivax
antigen
good
marker
acquir
immun
p
vivax
import
potenti
sourc
malaria
vaccin
candid
insight
may
provid
studi
anim
model
ie
primat
determin
experiment
protect
efficaci
antibodi
p
vivax
blood
infect
well
assess
reactiv
peptid
select
promis
candid
vaccin
develop
